New scans could sharpen prostate cancer detection

NCT ID NCT07568613

Recruiting now Diagnosis Sponsor: German Oncology Center, Cyprus Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two advanced imaging techniques, PSMA PET/CT and MRI-RSI, against the standard MRI to see which finds and outlines prostate tumors most accurately. Fifty men with newly diagnosed, higher-risk prostate cancer will undergo all scans and a targeted biopsy. The goal is to improve personalized treatment planning by reducing errors in tumor detection and measurement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI-RSI and PSMA PET/CT imaging
What this could lead to: If successful, this could lead to more accurate tumor detection and treatment planning for prostate cancer, potentially reducing the need for repeat biopsies.
What could go wrong: This is a small, early-stage study (50 participants) comparing imaging methods, not testing a treatment. Results may not apply to all patients, and the new techniques might not prove better than current MRI.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

German Oncology Center
RECRUITING

Limassol, 4108, Cyprus

More trials for these conditions

Other studies related to the condition(s) this trial covers.